# Champions Oncology, Inc.: Form 10-Q for the period ended Jan 31, 2020

- Company: [Champions Oncology, Inc.](/companies/csbr.md) (CIK 771856)
- Form: 10-Q
- Filed: 2020-03-16
- Accepted by EDGAR: Mar 16, 2020, 16:30 ET
- Period: 2020-01-31
- Accession: 0001628280-20-003637
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/771856/000162828020003637/csbr10-q1312020.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/771856/000162828020003637/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2020-01-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2019-11-01 to 2020-01-31 | $9.0m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months, 2019-05-01 to 2020-01-31 | $23.4m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2019-11-01 to 2020-01-31 | $4.3m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months, 2019-05-01 to 2020-01-31 | $12.0m | us-gaap:CostOfGoodsAndServicesSold |
| Research and development | 3 months, 2019-11-01 to 2020-01-31 | $1.4m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2019-05-01 to 2020-01-31 | $4.0m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2019-11-01 to 2020-01-31 | $433.0k | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2019-05-01 to 2020-01-31 | $109.0k | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2019-11-01 to 2020-01-31 | $12.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2019-05-01 to 2020-01-31 | $38.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2019-11-01 to 2020-01-31 | $407.0k | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2019-05-01 to 2020-01-31 | $72.0k | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2019-11-01 to 2020-01-31 | $0.03 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2019-05-01 to 2020-01-31 | $0.01 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2019-11-01 to 2020-01-31 | $0.03 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2019-05-01 to 2020-01-31 | $0.01 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2019-11-01 to 2020-01-31 | 13,673,672 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2019-05-01 to 2020-01-31 | 13,440,861 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2019-05-01 to 2020-01-31 | $360.0k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2019-05-01 to 2020-01-31 | $693.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2020-01-31 | $3.3m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2020-01-31 | $8.1m | us-gaap:AssetsCurrent |
| Total assets | at 2020-01-31 | $15.1m | us-gaap:Assets |
| Current liabilities | at 2020-01-31 | $8.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2020-01-31 | $11.9m | us-gaap:Liabilities |
| Shareholders' equity | at 2020-01-31 | $3.2m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 15,428 characters.

*The following discussion of our historical results of operations and our liquidity and capital resources should be read in conjunction with the condensed consolidated financial statements and related notes that appear elsewhere in this report and our most recent annual report for the year ended April 30, 2019, as filed on Form 10-K.*

### Forward-Looking Statements

This Quarterly Report on Form 10-Q contains certain “forward-looking statements,” which include information relating to future events, future financial performance, strategies, expectations, competitive environment, regulation, and availability of resources. These forward-looking statements include, without limitation, statements regarding: proposed new programs; expectations that regulatory developments or other matters will not have a material adverse effect on our financial position, results of operations, or liquidity; statements concerning projections, predictions, expectations, estimates, or forecasts as to our business, financial and operational results, and future economic performance; and statements of management’s goals and objectives and other similar expressions concerning matters that are not historical facts. Words such as “may,” “should,” “could,” “would,” “predicts,” “potential,” “continue,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar expressions, as well as statements in future tense, identify forward-looking statements.

Forward-looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on information available at the time those statements are made or management’s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements.

Forward-looking statements speak only as of the date the statements are made. Factors that could cause actual results to differ from those discussed in the forward-looking statements include, but are not limited to, those described in “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended April 30, 2019, as updated in our subsequent reports filed with the SEC, including any updates found in Part II, Item 1A of this or other reports on Form 10-Q, if any. You should not put undue reliance on any forward-looking statements. We assume no obligation to update forward-looking statements to reflect actual results, changes in assumptions, or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. If we do update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.

### Overview and Recent Developments

We are engaged in the development and sale of advanced technology solutions and products utilized in the development and use of oncology drugs. Utilizing our TumorGraft Technology Platform (the "Platform"), a comprehensive Bank of unique, well chracterized PDX models, we provide select services to pharmaceutical and biotechnology companies seeking personalized approaches to drug development. By performing studies to predict the efficacy of oncology drugs, our Platform facilitates drug discovery with lower costs and increased speed of drug development as well as increased adoption of existing drugs.

Our Platform provides a novel approach to simulating the results of human clinical trials used in developing oncology drugs. It can cost up to $100,000 per patient in oncology clinical trials and the typical cost for each phase of development per year increases from approximately $3 million in the pre-clinical setting to approximately $150 million in phase III. Simulating trials before executing them provides benefits to both pharmaceutical companies and patients. Pharmaceutical companies can lower the risk of spending resources on drugs that do not show significant anti-cancer activities and increase the chance that the clinical development path they pursue will be focused on an appropriate patient population and a successful combination with other drugs.

We plan to continue our efforts to expand our TumorGraft Technology Platform in order to expand our TOS program. Our POS program will not be the focus of our growth moving forward.

In December 2019, a novel strain of coronavirus was first identified in Wuhan, Hubei Province, China. Any outbreak of contagious diseases, or other adverse public health developments, could have a material and adverse effect on our business operations. These could include disruptions or restrictions on our ability to travel, pursue partnerships and other business transactions, receive shipments of biologic materials, as well as be impacted by the temporary closure of the facilities of suppliers. We are actively monitoring the coronavirus outbreak and its potential impact on our supply chain and operations. While we do not expect that the virus will have a material adverse effect on our business or financial results at this time, we are unable to accurately predict the impact that the coronavirus will have due to various uncertainties, including the ultimate geographic spread of the virus, the severity of the disease, the duration of the outbreak, and actions that may be taken by governmental authorities.

### Liquidity and Capital Resources

Our liquidity needs have typically arisen from the funding of our research and development programs and the launch of new products, working capital requirements, and other strategic initiatives. In the past, we have met these cash requirements through cash, working capital management, proceeds from certain private placements and public offerings of our securities, and sales of products and services. For the nine months ended January 31, 2020, the Company had net income of approximately $72,000 and cash flow from operations of $360,000. As of January 31, 2020, the Company had an accumulated deficit of approximately $70.6 million, a working capital deficit of $0.3 million and cash of $3.3 million. We believe that our cash on hand, together with expected positive cash flows from operations for fiscal year 2020, are adequate to fund operations through at least 12 months from the filing of this 10-Q. However, should our revenue expectations not materialize, we believe we have cost reduction strategies that could be implemented without disrupting the business or restructuring the Company. Should the Company be required to raise additional capital, there can be no assurance that management would be successful in raising such capital on terms acceptable to us, if at all.

### Operating Results

The following table summarizes our operating results for the periods presented below (dollars in thousands):

|  | For the Three Months Ended January 31, 2020 | % of Revenue | 2019 | % of Revenue | % Change |
| --- | ---: | ---: | ---: | ---: | ---: |
| Oncology services revenue | $9,012 | 100.0% | $6,430 | 100.0% | 40.2% |
| **Costs and operating expenses:** |  |  |  |  |  |
| Cost of oncology services | 4,325 | 48.0 | 3,429 | 53.4 | 26.1 |
| Research and development | 1,391 | 15.4 | 1,269 | 19.7 | 9.6 |
| Sales and marketing | 1,307 | 14.5 | 879 | 13.7 | 48.7 |
| General and administrative | 1,556 | 17.3 | 1,223 | 19.0 | 27.2 |
| Total costs and operating expenses | 8,579 | 95.2 | 6,800 | 105.8 | 26.2 |
| Income (loss) from operations | $433 | 4.8% | $(370) | (5.9)% | 217.0% |

|  | For the Nine Months Ended January 31, 2020 | % of Revenue | 2019 | % of Revenue | % Change |
| --- | ---: | ---: | ---: | ---: | ---: |
| Oncology services revenue | $23,375 | 100.0% | $19,348 | 100.0% | 20.8% |
| **Costs and operating expenses:** |  |  |  |  |  |
| Cost of oncology services | 11,958 | 51.2 | 9,963 | 51.5 | 20.0 |
| Research and development | 4,035 | 17.3 | 3,550 | 18.3 | 13.7 |
| Sales and marketing | 3,155 | 13.5 | 2,138 | 11.1 | 47.6 |
| General and administrative | 4,118 | 17.6 | 3,311 | 17.1 | 24.4 |
| Total costs and operating expenses | 23,266 | 99.5 | 18,962 | 98.0 | 22.7 |
| Income (loss) from operations | $109 | 0.5% | $386 | 2.0% | (71.8)% |

20

### Oncology Services Revenue

Oncology services revenue was $9.0 million and $6.4 million for the three months ended January 31, 2020 and 2019, respectively, an increase of $2.6 million or 40.2%. Operating revenues were $23.4 million and $19.3 million for the nine months ended January 31, 2020 and 2019, respectively, an increase of $4.0 million or 20.8%. The increase in revenue for both the three and nine month periods is due to increased sales, both in number and size of studies, and continuing to expand our customer base. Additionally, customers are seeking more complex study designs and end point analysis testing, leading to larger contracts, which contributed to revenue growth.

### Cost of Oncology Services

Cost of oncology services for the three months ended January 31, 2020 and 2019 were $4.3 million and $3.4 million, respectively, an increase of $900,000 or 26.1%. For the three months ended January 31, 2020 and 2019, gross margins were 52.0% and 46.7%, respectively. The increase in cost of oncology services for the three-month period was mainly due to an increase in compensation and supply expenses. The overall expense increase is generally in line with the expected contribution based on the growth in revenue and study volume. Cost of oncology solutions for the nine months ended January 31, 2020 and 2019 were $12.0 million and $10.0 million, respectively, an increase of $2.0 million or 20.0%. For the nine months ended January 31, 2020 and 2019, gross margins were 48.8% and 48.5%, respectively. Gross margin varies based on timing differences between expense and revenue recognition and was impacted by the increase in costs on growing study volume in advance of revenue recognition. The increase in cost of oncology services for the nine-month period was mainly due to an increase in compensation and supply expenses related to the growth in revenue and study volume.

### Research and Development

Research and development expenses for the three months ended January 31, 2020 and 2019 were $1.4 million and $1.3 million, respectively. Research and development expenses for the nine months ended January 31, 2020 and 2019 were $4.0 million and $3.6 million, respectively, an increase of $485,000 or 13.7%. The increase for both the three and nine-month periods is due to increased compensation and lab supply expense as we continued to invest in research and development to offer new PDx models, ex-vivo assays and to expand our endpoint analysis testing.

### Sales and Marketing

Sales and marketing expenses for the three months ended January 31, 2020 and 2019 were $1.3 million and $0.9 million, respectively, an increase of $0.4 million, or 48.7%. Sales and marketing expenses for the nine months ended January 31, 2020 and 2019 were $3.2 million and $2.1 million, respectively, an increase of $1.0 million or 47.6%. The increase for both the three and nine-month periods is mainly due to compensation expense driven by the continued expansion of our sales force and commissions earned.

### General and Administrative

General and administrative expenses for the three months ended January 31, 2020 and 2019 were $1.6 million and $1.2 million, respectively, an increase of approximately $400,000, or 27.2%. The increase for the three-month period was mainly due to an increase in compensation and depreciation expenses as well as a non-recurring bad debt write-off. General and administrative expenses for the nine months ended January 31, 2020 and 2019 were $4.1 million and $3.3 million, respectively, an increase of approximately $807,000 or 24.4%. The increase for the nine-month period was mainly due to an increase in compensation, professional fees, and depreciation expenses offset by a reduction in recruiting costs.

### Inflation

Inflation does not have a meaningful impact on the results of our operations.

### Cash Flows

The following discussion relates to the major components of our cash flows:

#### Cash Flows from Operating Activities

Net cash provided by operating activities was $360,000 for the nine months ended January 31, 2020 compared to net cash provided by operating activities of $1.6 million for the nine months ended January 31, 2019, respectively. The reduction in cash provided by operating activities during the current period was primarily due to the operating loss in the first quarter ended July 31, 2019, and, a net decrease in working capital items due to timing differences in the ordinary course of business, including an increase in net accounts receivable of $334,000 and a decrease in accounts payable of approximately $913,000.

#### Cash Flows from Investing Activities

Net cash used in investing activities was $0.7 million and $0.7 million for the nine months ended January 31, 2020 and 2019, respectively. Cash used in investing activities was for the purchase of lab equipment required for the Company's new product and service offerings.

#### Cash Flows from Financing Activities

Net cash provided by financing activities was $378,000 for the nine months ended January 31, 2020 compared to the net cash provided by financing activities of $1.4 million for the nine months ended January 31, 2019, respectively. The reduction in net cash from financing activities is due to a decrease in option and warrant exercises during the current period.

### Critical Accounting Estimates and Policies

The preparation of these condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to apply methodologies and make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant estimates of the Company include, among other things, accounts receivable realization, revenue recognition (replacement of licensed tumors), valuation allowance for deferred tax assets, valuation of goodwill, and stock compensation and warrant assumptions. Actual results could differ from those estimates. The Company’s critical accounting policies are summarized in the Company’s Annual Report on Form 10-K, filed with the SEC on July 29, 2019.

### Recent Accounting Pronouncements

For detailed information regarding recently issued accounting pronouncements and the expected impact on our condensed consolidated financial statements, see Note 2, "Significant Accounting Policies" in the accompanying Notes to Condensed Consolidated Financial Statements included in Item 1 of this Report on Form 10-Q.

### Off-Balance Sheet Financing

We have no off-balance sheet debt or similar obligations. We have no transactions or obligations with related parties that are not disclosed, consolidated into or reflected in our reported results of operations or financial position. We do not guarantee any third-party debt.

## Controls and procedures

As filed, 1,602 characters.

### Evaluation of Disclosure Controls and Procedures

It is management’s responsibility to establish and maintain “disclosure controls and procedures” as such term is defined in Rule 13a-15(e) under the Securities Exchange Act of 1934. Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer have reviewed and evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this quarterly report. Based on that evaluation, our management, including our Chief Executive Officer and our Chief Financial Officer, have concluded that our disclosure controls and procedures were effective as of January 31, 2020 at the reasonable assurance level in ensuring that information required to be disclosed in the reports that we file or submit under the Securities Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and is accumulated and communicated to management, including our Chief Executive Officer and our Chief Financial Officer as appropriate, to allow timely decisions regarding required disclosure.

### Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting in connection with the evaluation required by Rule 13a-15(d) of the Exchange Act that occurred during the period covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 498 characters.

As a smaller reporting company, we are not required to provide the information required by this Item; however, the discussion of our business and operations should be read together with the Risk Factors set forth in our Annual Report on Form 10K filed with the Securities and Exchange Commission on July 29, 2019. Such risks and uncertainties have the potential to affect our business, financial condition, results of operations, cash flow, strategies or prospects in a material and adverse manner.

Filed Mar 16, 2020.
Source: SEC EDGAR, the filing index for accession 0001628280-20-003637. Last ingested by Listed: Nov 10, 2026, 03:33 ET. No prices; not investment advice.
